Hoth Therapeutics, Inc. (HOTH)

Hoth Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	4.21	6.13	3.82	1.91	2.93
Research & Development	3.48	4.93	7.53	2.89	2.12
Other Operating Expenses	0	0	2.75	2.5	2.66
Operating Expenses	7.69	11.07	14.1	7.3	7.71
Operating Income	-7.69	-11.07	-14.1	-7.3	-7.71
Other Expense / Income	0.15	0.31	0.18	-0.1	-0.01
Pretax Income	-7.85	-11.37	-14.28	-7.2	-7.7
Net Income	-7.85	-11.37	-14.28	-7.2	-7.7
Shares Outstanding (Basic)	3	1	1	0	0
Shares Outstanding (Diluted)	3	1	1	0	0
Shares Change	184.69%	34.07%	80.63%	34.90%	82.16%
EPS (Basic)	-2.30	-9.50	-16.02	-14.50	-21.00
EPS (Diluted)	-2.30	-9.50	-16.02	-14.50	-21.00
Free Cash Flow	-8.45	-9.3	-12.09	-6.13	-4.95
Free Cash Flow Per Share	-2.48	-7.76	-13.54	-12.40	-13.49
EBITDA	-7.85	-11.37	-14.28	-7.2	-7.7
Depreciation & Amortization	0	0	0	0	0
EBIT	-7.85	-11.37	-14.28	-7.2	-7.7

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).